Falconer. Could 3-71 be better than 2-73? Could you briefly explain their differences? Just looking down the road since the patent issue remains unclear.
I know it would help many on this board and help to relieve some of the anxiety surrounding the patent. Knowing 3-71 could be better and why should also help us understand where we stand in terms of negotiating strength and what we bring to the table.
Anavex is a cut above the rest. They understand and value safety and efficacy first. 2-73 seems to pass that test with flying colors.
Merry Christmas everyone. 2017 has a good shot at answering the desperate call of victims with Alzheimer's Disease and their caregivers to bring about real relief and true recovery. It seems nothing less than a paradigm shift is necessary to change the focus of other companies efforts to alleviate the symptoms of the disease instead of attacking the cause. Anavex is blazing the trail that could one day stop and reverse the symptoms by focusing on the cause.
News 
Market Data 
Discover 
